Since MGMT promoter hypermethylation is associated with better chemotherapy response, this may explain why women generally respond better to chemotherapy plus radiotherapy and have a better outcome in GBM than men [15,40] and suggests that sex differences in gene expression are important for survival and therapy response. This evidence concerns the gene MGMT and glioblastoma.